Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More spiked ED supplements recalled

This article was originally published in The Tan Sheet

Executive Summary

Los Angeles-based dietary supplement firms Barodon SF and Cosmos Trading voluntarily recalled products FDA found to contain aminotadalafil, an analogue of tadalafil, the active ingredient in Rx drugs used to treat erectile dysfunction. FDA told "The Tan Sheet" it detected the presence of the substance in the firms' products while testing "products promoted as dietary supplements for uses including enhanced sexual performance." The unapproved drugs marketed as supplements present a "threat to consumers because aminotadalafil may interact with nitrates found in some prescription drugs (such as nitroglycerin) and may lower blood pressure to dangerous levels," FDA says. The agency prompted a recall of unapproved tadalafil-containing products in January (1"The Tan Sheet," Jan. 29, 2007, In Brief). Barodon announced its V.MAX recall on March 15, and Cosmos announced its Rhino Max recall on March 16...
Advertisement

Related Content

Liviro3 recall

Topics

Advertisement
UsernamePublicRestriction

Register

PS100341

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel